Stephanie van Hoppe

63 Brain accumulation of osimertinib and its active metabolite is restricted by ABCB1 & ABCG2 37. Durmus S, Sparidans RW, Wagenaar E, et al. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar, Mol Pharm, 11 (2012) 3236-3245. 10.1021/mp3003144 38. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins, Proc Natl Acad Sci U S A, 8 (1997) 4028-4033. 39. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk, Nat Med, 2 (2005) 127-129. 10.1038/nm1186 40. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria, Proc Natl Acad Sci U S A, 24 (2002) 15649- 15654. 10.1073/pnas.202607599 41. vanWaterschoot RA, Lagas JS,Wagenaar E, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity, Cancer Res, 23 (2009) 8996-9002. 10.1158/0008-5472.CAN-09-2915 42. Rood JJM, van Bussel MTJ, Schellens JHM, et al. Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma, J Chromatogr B Analyt Technol Biomed Life Sci, (2016) 80-85. 10.1016/j.jchromb.2016.07.037 43. van Groen BD, van de Steeg E, Mooij MG, et al. Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants, Eur J Pharm Sci, (2018) 217-227. 10.1016/j.ejps.2018.08.042 44. MacLeod AK, Lin, Huang JT, et al. Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy, Clin Cancer Res, 9 (2018) 2138-2147. 10.1158/1078-0432.CCR-17-3555 45. Li W, Sparidans RW, Wang Y, et al. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability, Pharmacol Res, (2018) 47-55. 10.1016/j.phrs.2018.09.020 46. Pesic M, Markovic JZ, Jankovic D, et al. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs, J Chemother, 1 (2006) 66-73. 10.1179/joc.2006.18.1.66 47. Khalifa J, Amini A, Popat S, et al. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies, J Thorac Oncol, 10 (2016) 1627-1643. 10.1016/j.jtho.2016.06.002 48. Lagas JS, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation, Molecular cancer therapeutics, 2 (2010) 319-326. 10.1158/1535-7163. mct-09-0663 49. Oostendorp RL, Buckle T, Beijnen JH, et al. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib, Investigational new drugs, 1 (2009) 31-40. 10.1007/s10637-008-9138-z 50. Agarwal S, Sane R, Gallardo JL, et al. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux, The Journal of pharmacology and experimental therapeutics, 1 (2010) 147-155. 10.1124/jpet.110.167601 51. Kort A, Durmus S, Sparidans RW, et al. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1), Pharm Res, 7 (2015) 2205-2216. 10.1007/s11095-014-1609-7 52. Kort A, van Hoppe S, Sparidans RW, et al. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2), Mol Pharm, 10 (2017) 3258-3268. 10.1021/acs.molpharmaceut.7b00257 53. van Hoppe S, Sparidans RW, Wagenaar E, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation, Pharmacol Res, (2017) 43-50. 10.1016/j.phrs.2017.01.035 54. Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor, Journal of medicinal chemistry, 20 (2014) 8249-8267. 10.1021/jm500973a 55. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer, J Clin Oncol, (2018) JCO2018783118. 10.1200/JCO.2018.78.3118